Where to Invest now? | Portfolio Breakdown | Aditya Khemka, InCred

ELI5/TLDR

Aditya Khemka from InCred argues that the true art of investing lies not in finding great businesses but in buying them at the right price. He dissects his healthcare-heavy portfolio through a lens of macroeconomic stress: declining global efficiency, rising protectionism, and shrinking discretionary consumption force him to bet on non-discretionary sectors (healthcare, education) that will thrive regardless. His framework pivots on cash flow (not profits), antifragile business DNA, and asymmetric risk-reward bets—often buying cheap after markets overshoot downward.

The Full Story

The Macro Context: Deflationary Forces Amid Money Printing

Khemka opens with a provocative paradox. The last 40-50 years saw productivity and efficiency gains that should have driven prices down. Instead, central banks printed endlessly, creating inflation without backing. The natural state of a truly productive global economy should be deflationary; instead, we abandoned the gold standard and created an inverted world where inflation is celebrated as healthy.

He frames the coming decade as a reckoning. Money printing can’t continue forever without collapse. Governments face a trilemma: they can’t reduce debt (no one votes for austerity), can’t sustain spending (math breaks), and won’t tell citizens the truth. So consumption will slow. Globalization—the great efficiency engine of the past 40 years—reverses. Trust between nations erodes (Russia-Ukraine, China trade tensions). When India stops buying cheap Chinese goods and starts producing at home, costs rise, margins compress, and only businesses with pricing power survive.

The Investment Thesis: Bet on the Inelastic

In this deglobalizing, austere future, discretionary consumption—real estate, clothing, autos, jewelry—will flatline or decline. Non-discretionary sectors (healthcare, education, food) will persist. But here’s the market error: food and apparel stocks trade at the richest valuations despite targeting slower-growing markets. Healthcare stocks—targeting the fastest-growing consumption bucket (as wealth rises, health spend explodes: US went from 3% of GDP in 1950 to 18% today)—trade cheap.

The “holy grail” of investing is finding pockets of simultaneous earning growth and multiple expansion. Khemka builds his portfolio around three such pockets:

Healthcare (large bet): Non-discretionary, secular tailwind, misvalued
PSU banks (rotation thesis): Structural efficiency improvement not yet priced in; they’ve gone from 4% ROE to 12%, NPA profiles match private banks, yet valuations remain 0.6-1.2x book while private banks get 1.5-4x
NBFCs/MFIs (asymmetric bet): At multi-year valuation lows (0.5-1.5x book vs. 2-5x in normal times), NPAs at 8% (worst ever but a cyclical bottom), ROE temporarily negative. When credit cycles turn, earning growth + multiple expansion = 200% upside, downside capped at 20-30%.

The Cash Flow Lens: P&L as Makeup, Cash Flow as Reality

Khemka’s most visceral insight: P&L is a bride with two-hour makeup; cash flow is the girl when she’s woken up.

He demonstrates this with HCG (Healthcare Global), his largest holding. The P&L shows a 276x trailing multiple—“horribly expensive, don’t go near.” The cash flow shows 30-35x trailing, with secular straight-line growth over a decade, negative working capital (every rupee of Ebitda growth yields 1.2 rupees of cash), and nearly zero debt. Different story entirely.

By contrast, he pulls Shelby (another hospital chain) alongside HCG. Shelby has positive working capital of 70-75 days. They’re stranded with inventory (they bought a US implant business that blew up) and haven’t paid vendors in 4 years. On P&L metrics, both look similar. On cash flow, one is a secular compounder, the other a leverage bomb.

His metric of choice: EV/OCF (enterprise value to operating cash flow). HCG at 33-35x. Shelby implicitly much higher due to the working capital trap. Max Healthcare at 90x. He’ll hold HCG until it hits 100x EV/OCF; by then, absolute returns could be 6-7x as earnings compound and the multiple stays reasonable.

Business Model Deep Dives: The Taxonomy of Moats

Healthcare Global (super-specialty cancer): Sticky patient base (cancer patients stay for life). Unlike multi-specialty hospitals with 80% “treadmill” patients (maternity, ortho, one-off), cancer centers compound. Market cap tiny relative to peers, yet better business model. KKR acquisition validates play; PE brings operational discipline. Entry thesis: debt trap at the bottom, but India can’t afford HCG to fail. Margin expansion path proven (KKR lifted Max from 8% EBITDA margins to 30% via outsourcing non-core ops and procurement centralization).

Thyrocare (diagnostics, B2B model): During COVID, diagnostic margins soared on RTPCR tests. Multiples expanded to 60-70x because market extrapolated unsustainable COVID profits. Khemka stayed out. Once COVID ended and multiples collapsed to 20-30x, he entered. Thesis violated when pharmacy (main platform) imploded, but margin of safety held—bought at 650, never went to his pain threshold. Pledged shares (71% backing an NBFC loan) looked scary; reality: NBFC can’t sell without tanking stock, so pledge is toothless.

Krishna Diagnostics (B2G, PPP model): Government contracts + guaranteed volume = unique risk. Revenue from 8 cr (2011, two hospitals) to 750 cr (today, 17-18 states). Growth engine: voting math. Hospitals in poor areas run by Krishna → health outcomes improve → ruling party gets votes → more contracts. He explicitly frames it as a “democracy play.” When IT raids hit and stock crashed from 900 to 450, he did homework, spoke to states, and bought. Thesis: India can’t unwind this—it’s a bet on political incentives, not fundamentals alone.

RPG Lifesciences (branded pharma): Margins were 6-7% (vs. 30-40% for peer branded businesses). Growth flat. No management. New CEO (Yugal Sikri, from Novartis, known as a taskmaster) joined. Entry at 350-400. Today 2,400+. Thesis: management turnaround. He milked existing brands (Azoran, Lomot, Neproin—each with decades of equity) and added new ones. The skill wasn’t building brands; it was unlocking dormant ones.

Jubilant Pharma/FDC/Vima Labs/Metropolis: Each a lesson in moat anatomy. Jubilant: multiple verticals (radioactive, allergy venom, generics, CDMO). When US FDA hit generics, he valued profitable arms at going-concern multiples, loss-making arms at book value. Assumed worst (generics = zero) and still got upside. FDC: household brands (Electrol, Eneral, Zinetac) with 23% CAGR since IPO in 1997. Undervalued because management is low-profile and promoters don’t court investors. CROs like Vima trade on trust moats (pharma shares IP for human trials) that take decades to build—new entrants face 10-20 year cycles.

The Mistakes (and Learning)

Walkart: Sell India to save the US generics business. Classic capital misallocation. He exited at a loss. It took Walkart 10 years to turn around (he exited ~2014, current date 2025). Lesson: sometimes exit bets that violate your thesis, even at losses, rather than hold for “the turnaround.” (Though he notes with wry humor: “The stock went 4x after I exited.”)

Alchemist (brand-building in generics): He loves the business model but won’t buy because valuations never dip enough. That’s discipline.

The Sizing Framework

Risk-reward ratio + confidence level + liquidity = position size. A 10:1 bet gets higher weight than a 5:1. But if he has conviction on a 10:1 play in a 50,000-cr AUM fund and the stock’s market cap is 7,000 cr, he hits a ceiling—can’t take 10% of the firm’s portfolio in one name. So he sizes down to what liquidity allows. Confidence in forecasting also matters: high for hospitals and diagnostics (he understands the models), low for steel (no edge on global pricing). Management pedigree constrains size too—if the CEO talks a big game but hasn’t walked the talk, he takes a “wait and watch” small position.

The Discipline: Framework Over Prediction

He preaches restraint and framework. Don’t read 500 books and lose your originality. Most investors conflate speed with efficiency; they’re different. Effectiveness (quality of work) matters; efficiency comes with time. His portfolio churns at 15-17% annually. Exits happen when:

Bull-case valuation hits (predetermined threshold—sell unless fundamentals improve)
Investment thesis violated (management did XYZ instead of ABC)

Hold periods average 6 years. He doesn’t chase trends. IPOs are almost always overpriced (the person who knows most is selling). Wait 3-4 quarters, then reassess. The art of investing is the ability to restrict impulses to act. Not trading is the loudest action.

Key Takeaways

Efficiency is reversing globally: deglobalization + protectionism = cost inflation + margin compression. Only pricing-power businesses and inelastic demand sectors survive.
Healthcare is the secular winner: as India’s GDP per capita rises, healthcare spend will grow from 3% to 7-8% of consumption (following the US pattern). Food and apparel will shrink as % of spend.
Valuation is paramount: margin of safety is the entire game. Buy good businesses at great prices, not great businesses at good prices.
Cash flow is reality: P&L is easily manipulated; operating cash flow, working capital cycles, and cash conversion matter.
Business DNA emerges in downturns: antifragile businesses improve during crises; fragile ones survive; dirty ones fail. Invest in management behavior during bad patches.
Moats are trust, scale, and geography: diagnostic CROs, hospital networks, and brands with geographic stickiness (Metropolis in Mumbai) have durable edges.
Risk-reward asymmetry is the framework: 10:1 upside-to-downside bets get weight. Pair with high confidence and liquidity constraints.
PSU banks and NBFCs are rotation plays: structural efficiency + valuation reset = dual tailwind. PSU banks now match private bank metrics but trade at 0.6x book; NBFCs are at cycle lows.

Claude’s Take

This is a masterclass in bottom-up stock analysis paired with a coherent macro narrative. Khemka doesn’t short-term trade; he builds portfolios through deep company research, manages for 6-year holds, and actively exits when theses break. His framework is brutally logical: if money printing can’t sustain forever, if globalization reverses, if consumers become poorer, then bet on things people must consume. The healthcare thesis is not new (everyone knows healthcare grows faster than GDP), but the execution—finding undervalued super-specialty models, diagnostics with network effects, and management-driven turnarounds—shows discipline.

What’s less obvious is his macro bearishness dressed in sector optimism. He’s not bullish on India. He’s bullish on specific business models within a world of slower growth, austerity, and protectionism. That’s a meaningful distinction. The PSU bank and NBFC bets are also fascinating—not contrarian views (everyone sees PSUs improving), but contrarian weightings (he sizes them big because the market hasn’t revalued yet).

His mistakes (Walkart, not buying Sherry) are instructive: he’s willing to miss returns if the valuation story breaks down, and he won’t hold “good companies at bad prices” just for mean reversion. That rationality is rare.

The cash-flow framework is immediately actionable: pull HCG vs. Shelby side-by-side, run OCF trends, and the difference becomes stark. Most retail investors fixate on P/E multiples. He forces you to ask whether those earnings are real (working capital, capital intensity, cash conversion).

Worth noting: this is healthcare-centric. If you hate the sector or believe the macro narrative is wrong, the picks won’t resonate. But the framework—macro stress, sector selection, business model differentiation, valuation discipline—is universal.

Score: 8/10. Deep insight, clear articulation, actionable frameworks, but the macro premise (deglobalization collapse) is debatable and the execution requires genuine homework. Not life-changing but genuinely instructive for anyone serious about bottom-up stock picking.

Where to Invest now? | Portfolio Breakdown | Aditya Khemka, InCred | Exploring Minds